Strategic Growth SyntheticMR operates in the medical imaging space with a focus on brain MRI biomarkers and quantitative analysis, presenting opportunities to expand within hospitals, radiology departments, and neurology/neuroscience centers that require rapid, quantitative imaging solutions.

Leadership Changes Recent C-suite transitions including new CEO appointments and interim leadership indicate a period of strategic realignment, which can open doors for renewed partnerships, pilot programs, and revised procurement approaches.

Expansion Through Acquisition The acquisition of Combinostics US Inc. signals a growth strategy and broader product integration potential, enabling cross-sell of SyMRI with complementary biomarker tools to larger hospital networks and international markets.

Global Reach Headquartered in Sweden with sales representation in the USA, Europe, Japan, and India, there are multi-region sales opportunities and the potential to tailor regional deployments, regulatory approvals, and support models for different markets.

AI and Quantitative Focus Investments in AI-powered quantitative brain imaging and 3D parcellation capabilities position SyntheticMR to address demand for automated, objective biomarkers, making a compelling case for partnerships with MRI manufacturers, hospitals pursuing precision medicine, and research institutions.